淋巴样增强结合因子1在B细胞慢性淋巴增殖性疾病中的表达

doi:10.3969/j.issn.1006-5725.2024.07.018

Abstract

Abstract:

Objective To investigate the expression of lymphoid enhancer binding factor 1 （LEF1） in B cell chronic lymphoproliferative disorders （B?CLPD） and estimate its value in the differential diagnosis of the subtype of B?CLPD. Methods A retrospective study was conducted on 58 patients diagnosed with B?CLPD by using bone marrow biopsy samples or lymphnode biopsy samples from Hematology Department of The Second People's Hospital of Wuhu from September 2018 to June 2023， as well as 20 bone marrow biopsy samples which were diagnosis as non?hematologic malignancy in the control group. Immunohistochemical method was used to detect the expression of LEF1 in 78 samples， and statistical analysis was conducted. Results In all 78 cases， 16 of 20 chronic lymphocytic leukemia （CLL） patients were LEF1 positive， the positive rate was 80%； mantle cell lymphoma 1/12； Follicular lymphoma 1/5； marginal zone cell lymphoma 0/11； Lymphoplasmacyticlymphom 0/8； hairy cell leukemia 0/2； in Control group no patient was LEF1 positive（P = 0.000）. The expression of LEF1 is correlated with CD200 and CLL score（P < 0.05）. In the LEF1 negative group with 4 CLL patients， 2 were detected with +12 chromosomal abnormality， the detective rate was higher than that of the LEF1 positive group（P > 0.05）. Conclusion LEF1 was a sensitive and specific diagnosis marker in CLL and B?CLPD subtype.

Key words: B cell chroniclymphoproliferative disorders, lymphoid enhancer binding factor 1, chronic lymphocytic leukemia, diagnosis

CLC Number:

R733.4

Min ZHAO,Ping NI,Huiying ZHAI,Xiaoke JIN,Yuqiong. YANG. Analysis of the expression of lymphoid enhancer binding factor 1 in B cell chronic lymphoproliferative disorders[J]. The Journal of Practical Medicine, 2024, 40(7): 984-988.

Figures/Tables 5

Tab.1

Fig.1

Tab.2

Tab.3

Tab.4

References 22

1	中华医学会血液学分会、中国抗癌协会血液肿瘤专业委员会．中国B细胞慢性淋巴增殖性疾病诊断专家共识（2014年版）［J］. 中华血液学杂志， 2014， 35（4）：367-370.
2	中华医学会血液学分会白血病淋巴瘤学组，中国抗癌协会血液肿瘤专业委员会，中国慢性淋巴细胞白血病工作组. 中国慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的诊断与治疗指南（2018年版）［J］. 中华血液学杂志， 2018， 39（5）： 353-358. doi:10.3760/cma.j.issn.0253-2727.2018.05.001 doi: 10.3760/cma.j.issn.0253-2727.2018.05.001
3	QI Y， SHAN Y， LI S， et al. LncRNA LEF1-AS1/LEF1/FUT8 Axis Mediates Colorectal Cancer Progression by Regulating α1， 6-Fucosylationvia Wnt/β-Catenin Pathway［J］. Dig Dis Sci， 2022，67（6）：2182-2194. doi:10.1007/s10620-021-07051-w doi: 10.1007/s10620-021-07051-w
4	CHEN D， LI K， PAN L， et al. TCF7 and LEF-1 downregulation in sepsis promotes immune suppression by inhibiting CD4⁺ T cell proliferation［J］. Microb Pathog， 2023，184：106362. doi:10.1016/j.micpath.2023.106362 doi: 10.1016/j.micpath.2023.106362
5	SWERDLOW S H， CAMP E， HARRIS N L，et al. WHO classification of tumours of haematopoietic and lymphoid tissues［M］.4th ed. Lyon： IARC Press， 2017.
6	SORIGUE M， JURADO R. Flow cytometry in leukaemic B cell lymphoproliferative disorders. New scores， same old concerns［J］. Int J Lab Hematol， 2022，44（6）：e262-e264. doi:10.1111/ijlh.13922 doi: 10.1111/ijlh.13922
7	王巍，刘文鑫，黄永彬，等，急性白血病β-catenin与LEF 1基因表达的相关性［J］. 实用医学杂志， 2018，34（12）：1986-1989.
8	GU S， LIU F， XIE X，et al. β-Sitosterol blocks the LEF-1-mediated Wnt/β-catenin pathway to inhibit proliferation of human colon cancer cells［J］. Cell Signal， 2023，104：110585. doi:10.1016/j.cellsig.2022.110585 doi: 10.1016/j.cellsig.2022.110585
9	SANTIAGO L， DANIELS G， WANG D， et al. Wnt signaling pathway protein LEF1 in cancer， as a biomarker for prognosis and a target for treatment［J］. Am J Cancer Res， 2017，7（6）：1389-1406.
10	CARR T， MCGREGOR S， DIAS S， et al. Oncogenic and Tumor Suppressor Functions for Lymphoid Enhancer Factor 1 in E2a^-/-T Acute Lymphoblastic Leukemia［J］. Front Immunol， 2022，18（13）：845488.
11	陈雪，芮炜炜，毕珂，等. 淋巴样增强结核因子1蛋白表达在淋巴母细胞淋巴瘤/急性淋巴细胞白血病中的诊断及鉴别诊断研究［J］. 中华病理学杂志， 2021，50（3）：207-212.
12	MENTER T， TRIVEDI P， AHMAD R， et al. Diagnostic Utility of Lymphoid Enhancer Binding Factor 1 Immunohistochemistry in Small B-Cell Lymphomas［J］. Am J ClinPathol， 2017，147（3）：292-300.
13	RAVINDRAN A， KURTIN P J， KING R L，et al. Aberrant expression of lymphoid enhancer-binding factor 1 in Hodgkin lymphoma［J］. Hum Pathol， 2022，125：2-10. doi:10.1016/j.humpath.2022.04.004 doi: 10.1016/j.humpath.2022.04.004
14	O'MALLEY D P， LEE J P， BELLIZZI A M. Expression of LEF1 in mantle cell lymphoma［J］. Ann Diagn Pathol， 2017，26：57-59. doi:10.1016/j.anndiagpath.2016.09.016 doi: 10.1016/j.anndiagpath.2016.09.016
15	MENTER T， DIRNHOFER S， TZANKOV A. LEF1： a highly specific marker for the diagnosis of chronic lymphocytic B cell leukaemia/small lymphocytic B cell lymphoma［J］. J Clin Pathol，2015，68（6）：473-478. doi:10.1136/jclinpath-2015-202862 doi: 10.1136/jclinpath-2015-202862
16	RANGAN A， REINIG E， MCPHAIL E D， et al. Immunohistochemistry for LEF1 and SOX11 adds diagnostic specificity in small B-cell lymphomas［J］. Hum Pathol， 2022，121：29-35. doi:10.1016/j.humpath.2022.01.001 doi: 10.1016/j.humpath.2022.01.001
17	AL-ZUBAIDI H K， HUGHES S F. The Use of CD200 in the Differential Diagnosis of B-Cell Lymphoproliferative Disorders［J］. Br J Biomed Sci， 2023，26（80）：11573.
18	KOHNKE T， WITTMANN V K， BÜCKLEIN V L，et al. Diagnosis of CLL revisited： increased specificity by a modified five-marker scoring system including CD200［J］. Br J Haematol，2017，179（3）：480-487. doi:10.1111/bjh.14901 doi: 10.1111/bjh.14901
19	REA B， BAILEY N G. Additional characterization of LEF1 expression in nodular lymphocyte predominant Hodgkin lymphoma and classic Hodgkin lymphoma［J］. Ann Diagn Pathol， 2021，52：151730. doi:10.1016/j.anndiagpath.2021.151730 doi: 10.1016/j.anndiagpath.2021.151730
20	SOLIMAN D S， AL-KUWARI E， SIVEEN K S， et al. Downregulation of Lymphoid enhancer-binding factor 1 （LEF-1） expression （by immunohistochemistry and/flow cytometry） in chronic Lymphocytic Leukemia with atypical immunophenotypic and cytologic features［J］. Int J Lab Hematol， 2021，43（3）：515-525. doi:10.1111/ijlh.13420 doi: 10.1111/ijlh.13420
21	PATEL N， DURKIN L， BODO J， et al. Immunohistochemical Expression of Lymphoid Enhancer Binding Factor 1 in CD5-Positive Marginal Zone， Lymphoplasmacytic， and Follicular Lymphomas［J］. Am J Clin Pathol， 2020，153 （5）：646-655. doi:10.1093/ajcp/aqz207 doi: 10.1093/ajcp/aqz207
22	MOLLSTEDT J， MANSOURI L， ROSENQUIST R. Precision diagnostics in chronic lymphocytic leukemia： Past， present and future［J］. Front Oncol， 2023，21 （13）：1146486 .

	CLL	MCL	FL	MZL	LPL	HCL
例数	20	12	5	11	8	2
男/女	17/3	12/0	1/4	7/4	5/3	2/0
年龄［M（P₂₅，P₇₅），岁］	66（58，72）	70（66， 79）	55（52，59）	68（59，74）	59（50，73）	54.5（54，55）
标本（骨髓/其他组织）	18/2	11/1	3/2	7/4	8/0	2/0
白细胞数［M（P₂₅，P₇₅），×10⁹/L］	31.80（10.40，74.64）	6.70（3.86，25.65）	30.50（6.45，68.66）	10.89（2.69，34.00）	4.82（2.94，5.33）	9.10（0.7，15.4）
贫血	7/20	6/11	3/5	8/11	8/8	1/2
血小板减少	6/20	4/11	1/5	5/11	5/8	1/2
脾大	9/20	8/11	3/5	6/11	3/8	2/2

	CLL组	MCL组	FL	MZL	LPL	HCL	对照组
例数	20	12	5	11	8	2	20
LEF1阳性	16	1	1	0	0	0	0
似然比	39.943
P值	0.000

	LEF1⁺ （n = 17）	LEF1^- （n = 15）	χ²值	P值
CD22⁺*	14	15	1.10	0.271
CD79b⁺*	11	13	1.02	0.307
FMC7⁺*	1	12	3.90	< 0.001
CD200⁺*	16	4	3.57	< 0.001
CD23⁺	16	3	3.90	< 0.001
CCND1⁺	1	11	3.57	< 0.001
SOX11⁺	1	11	3.57	< 0.001

[1]	Yuxin CHENG,Liang LIU,Shiyu DONG,Shengchao LI,Meng ZHANG. Research advances in exosomal proteins， mRNA and non⁃coding RNA regulation of Hepatocellular Carcinoma [J]. The Journal of Practical Medicine, 2024, 40(6): 748-755.
[2]	Juan TANG,Yi LI,Liqiong ZHAI,Shaowen LIU,Yong SHEN,Shuo CONG,Yongmei. LIU. The diagnostic value of miR⁃571 levels in blood from the peripherals in liver fibrosis [J]. The Journal of Practical Medicine, 2024, 40(5): 653-657.
[3]	Weifeng LIU,Zheng DAI,Yibin ZHOU,Kaiwen FENG,Kai WEI,Gule SUN,Dongrong YANG,Jin. ZHU. The value of urine protein kinase Y⁃linked gene promoter site methylation in early diagnosis of prostate cancer [J]. The Journal of Practical Medicine, 2024, 40(5): 688-694.
[4]	Haijing CHEN,Yaying YANG,Wei ZHAO,Jihong HU,Li WU,Linglin ZHENG,Yan WU,Qingqing LI. Contrast⁃enhanced CT and MRI in differentiating squamous cell carcinoma of the nasal cavity and sinuses from lymphoma [J]. The Journal of Practical Medicine, 2024, 40(3): 394-399.
[5]	Chao SHENG,Zhijian. WANG. Early identification， standardized diagnosis and treatment of placenta accreta spectrum disorders [J]. The Journal of Practical Medicine, 2024, 40(21): 2965-2970.
[6]	Shijun LUO,Lizi ZHANG,Dunjin. CHEN. Diagnosis， prevention and treatment of placenta accreta spectrum with non⁃traumatic factors [J]. The Journal of Practical Medicine, 2024, 40(21): 2971-2975.
[7]	Yu LIU,Li WANG,Bingfang CHEN,Kewen SUN,Yin. ZHANG. The efficacy of pancreatic fluid molecular biomarkers for diagnosis of pancreatic cancer [J]. The Journal of Practical Medicine, 2024, 40(21): 3101-3106.
[8]	Lu LIU,Xiaoji ZHU,Yuxu. ZHONG. Chronic cough： Current status and prospects [J]. The Journal of Practical Medicine, 2024, 40(21): 3107-3112.
[9]	Ling ZHU,Dewang REN,Runyang MA,Guowei LIANG,Xuejun. DOU. Methylation levels of the HIST1H4F gene mRNA region DNA and its diagnostic value in lung cancer tissues [J]. The Journal of Practical Medicine, 2024, 40(19): 2726-2732.
[10]	Zhijie HE,Weichao LI,Minghui HE,Xiaotong CHEN,Zhao LIN,Yaowei. ZHI. Rapid diagnosis of invasive candidiasis by droplet digital PCR [J]. The Journal of Practical Medicine, 2024, 40(19): 2738-2746.
[11]	Li′na LIU,Heming WU,Zhiyuan ZHENG,Shuxian HUANG,Lingna. SHE. Application of ultrasound evaluation of NT thickening and nasal bone dyscalcification combined with CMA in prenatal diagnosis of fetuses [J]. The Journal of Practical Medicine, 2024, 40(19): 2755-2759.
[12]	Qingwei ZHANG,Rutie. YIN. Hotspots and advances on diagnosis and treatment for cervical cancer [J]. The Journal of Practical Medicine, 2024, 40(17): 2357-2362.
[13]	Wei ZHANG,Xiyang HU,Yunna ZHANG,Lingling SHEN,Minhui LI,Shasha SONG,Jian. ZHANG. The combination of dual⁃energy CT and musculoskeletal ultrasonography has shown promise in distinguishing between calcium pyrophosphate deposition disease and gouty arthritis [J]. The Journal of Practical Medicine, 2024, 40(17): 2477-2482.
[14]	Shuting YANG,Shuoming LUO,Zhiguang. ZHOU. A new vision of diabetes classification： A shift from clinical manifestation to etiological molecular mechanism [J]. The Journal of Practical Medicine, 2024, 40(16): 2199-2205.
[15]	Jie YANG,Chunhong LI,Jingfei HUANG,Zhiwei CHEN,Lin. LIU. The expression and clinical significance of hsa_circ_0003922 in endometrioid carcinoma [J]. The Journal of Practical Medicine, 2024, 40(14): 1975-1980.

Analysis of the expression of lymphoid enhancer binding factor 1 in B cell chronic lymphoproliferative disorders

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 5

References 22

Related Articles 15

Recommended Articles

Metrics

Comments